The SOLO-1 trial (2018) established maintenance therapy with olaparib in newly diagnosed advanced ovarian cancer. Which patient population was enrolled in SOLO-1?
- A All women with advanced ovarian cancer regardless of BRCA status
- B Women with BRCA1/2 mutation and complete or partial response after platinum-based chemotherapy ✓
- C Women with homologous recombination-deficient (HRD) tumours only
- D Women with recurrent platinum-sensitive ovarian cancer
Correct answer: B. Women with BRCA1/2 mutation and complete or partial response after platinum-based chemotherapy
Explanation
SOLO-1 randomised women with newly diagnosed FIGO Stage III–IV high-grade serous or endometrioid ovarian cancer who had a germline or somatic BRCA1/2 mutation and had achieved a complete or partial response to first-line platinum-based chemotherapy. Olaparib maintenance therapy reduced the risk of disease progression or death by 70% (HR 0.30). PAOLA-1 and PRIMA trials extended PARP inhibitor maintenance to HRD-positive and all-comers respectively.
Reference: Shaw's Textbook of Gynaecology, 17th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.